Swarm emerges from stealth, targeting advanced solid cancers

Armed with a novel T cell platform, London-based biotech Swarm Oncology emerges from stealth, targeting advanced solid cancers.

Swarm, co-founded by renowned T cell therapy manufacturing expert and immunologist John Campbell and Delin Ventures, announced that long-time pharma exec Martin Olin will serve as its first CEO.

According to the biotech, its Swarm-T platform leverages immune system priming with proprietary ex vivo cell processing to generate unprecedented, large numbers of T cells with desired phenotypes to home, infiltrate and kill cancer cells. This enables non-exhausted immune responses against solid cancers, overcoming key limitations of current immunotherapy approaches.

Swarm, which notes two early-stage assets on its website, expects to advance its first therapeutic candidate into clinical trials in the next 12-15 months.